Journal: Obstetrics and Gynecology
Article Title: Preterm Birth Frequency and Associated Outcomes From the MATISSE (Maternal Immunization Study for Safety and Efficacy) Maternal Trial of the Bivalent Respiratory Syncytial Virus Prefusion F Protein Vaccine
doi: 10.1097/AOG.0000000000005817
Figure Lengend Snippet: Preterm births by income region ( A ) and relative risk for preterm birth overall and by country ( B ). Shown are data from the newborn and infant safety population. A. Numbers above the bars are the preterm birth rate (less than 37 weeks of gestational age [GA]) overall and by World Bank income region. Also shown is the relative risk (95% CI). In the overall group, the rate of GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in both the respiratory syncytial virus prefusion F protein–based vaccine (RSVpreF) and placebo groups. In the high-income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the placebo group. In the non–high-income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the RSVpreF group. In the upper-middle–income group, the preterm birth rate at a GA at birth of 24–less than 28 weeks was less than 0.1% (n=1) in the RSVpreF group. B. Countries with more than five preterm births overall. Countries included in each income region are summarized in Appendix 2, available online at http://links.lww.com/AOG/D944 . n, number of newborns and infants born preterm; N, total number of infants.
Article Snippet: The overall preterm birth rate in MATISSE was lower than background rates in countries with sufficient participant–event numbers enabling interpretation (Argentina, Japan, South Africa, United States); for example, in South Africa, the RSVpreF group preterm birth rate was 8.3% compared with the national estimate of 13%.
Techniques: Virus